戻る
Beam Therapeutics Inc (BEAM)価格
BEAM 株価推移チャート
BEAM 収入
Beam Therapeutics Inc
$31.22
-2.58%
$-0.82
終値： Jan 16, 16:00:00 GMT-5
$31.8
1.88%
$0.58
アフターマーケット：Jan 16, 20:00:00 GMT-5
主要データ
前終値
$32.05
始値
$31.98
当日レンジ
$30.78 - $32.24
52週レンジ
$13.52 - $36.44
取引高
1.6M
平均取引高
2.1M
1株当たり利益(TTM)
-4.43
配当利回り
--
時価総額
$3.2B
BEAMとは何ですか？
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 483 full-time employees. The company went IPO on 2020-02-06. The firm's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).